latest news releases from the newsroom
MediciNova Reports Clinical Results From Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
SAN DIEGO, April 7, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced positive clinical findings from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis (MS). The second year findings expand upon the results from the first year of this study reported previously.
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. Announces Patent Filing On Genetic Engineering and Gene Splicing Technology
LANSING, Mich., April 7, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) announced today that Dr. Malcolm Fraser, a scientific consultant to Kraig, and a member of its Scientific Advisory Board, is the named inventor in a now pending provisional patent application describing a system and methodology for redirecting a cell's natural DNA repair processes to perform site-directed cleavage and targeted genetic insertion. The patent describes applications for producing genetically engineered silk fibers. The patent was filed earlier this year by the University of Notre Dame, where Dr. Fraser heads the University's Laboratory of Molecular Virology.